Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Berdel AF, Röllig C, Burkhard-Meier C, Tembrink M, Unglaub JM, Sauer T, Crysandt M, Jost E, Jaeger P, Kiefel C, Fransecky L, Braitsch K, Götze K, Wille K, Schäfer-Eckart K, Metzeler K, Hilber S, Ronnacker J, Kemper M, Hölscher N, Wethmar K, Schroeder T, Herold S, Poitz D, Steffen B, Rank A, Hänel M, Middeke JM, Kaufmann M, Burchert A, Schetelig J, Platzbecker U, Thiede C, Stelljes M, Lenz G, Serve H, Baldus C, Bornhäuser M, Müller-Tidow C, Mikesch JH, Frenzel L, Hanoun M, Ruhnke L, Schliemann C

Open source

DOI
10.3324/haematol.2026.301102
Published
2026 Aug 20
Container
Haematologica
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2026.301102,
  title = {Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.},
  author = {Berdel AF and Röllig C and Burkhard-Meier C and Tembrink M and Unglaub JM and Sauer T and Crysandt M and Jost E and Jaeger P and Kiefel C and Fransecky L and Braitsch K and Götze K and Wille K and Schäfer-Eckart K and Metzeler K and Hilber S and Ronnacker J and Kemper M and Hölscher N and Wethmar K and Schroeder T and Herold S and Poitz D and Steffen B and Rank A and Hänel M and Middeke JM and Kaufmann M and Burchert A and Schetelig J and Platzbecker U and Thiede C and Stelljes M and Lenz G and Serve H and Baldus C and Bornhäuser M and Müller-Tidow C and Mikesch JH and Frenzel L and Hanoun M and Ruhnke L and Schliemann C},
  year = {2026},
  journal = {Haematologica},
  doi = {10.3324/haematol.2026.301102},
  url = {https://doi.org/10.3324/haematol.2026.301102}
}

RIS

TY  - JOUR
TI  - Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.
AU  - Berdel AF
AU  - Röllig C
AU  - Burkhard-Meier C
AU  - Tembrink M
AU  - Unglaub JM
AU  - Sauer T
AU  - Crysandt M
AU  - Jost E
AU  - Jaeger P
AU  - Kiefel C
AU  - Fransecky L
AU  - Braitsch K
AU  - Götze K
AU  - Wille K
AU  - Schäfer-Eckart K
AU  - Metzeler K
AU  - Hilber S
AU  - Ronnacker J
AU  - Kemper M
AU  - Hölscher N
AU  - Wethmar K
AU  - Schroeder T
AU  - Herold S
AU  - Poitz D
AU  - Steffen B
AU  - Rank A
AU  - Hänel M
AU  - Middeke JM
AU  - Kaufmann M
AU  - Burchert A
AU  - Schetelig J
AU  - Platzbecker U
AU  - Thiede C
AU  - Stelljes M
AU  - Lenz G
AU  - Serve H
AU  - Baldus C
AU  - Bornhäuser M
AU  - Müller-Tidow C
AU  - Mikesch JH
AU  - Frenzel L
AU  - Hanoun M
AU  - Ruhnke L
AU  - Schliemann C
PY  - 2026
JO  - Haematologica
DO  - 10.3324/haematol.2026.301102
UR  - https://doi.org/10.3324/haematol.2026.301102
ER  -

APA

AF, B., C, R., C, B., M, T., JM, U., T, S., M, C., E, J., P, J., C, K., L, F., K, B., K, G., K, W., K, S., K, M., S, H., J, R., M, K., N, H., K, W., T, S., S, H., D, P., B, S., A, R., M, H., JM, M., M, K., A, B., J, S., U, P., C, T., M, S., G, L., H, S., C, B., M, B., C, M., JH, M., L, F., M, H., L, R., & C, S. (2026). Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.. Haematologica. https://doi.org/10.3324/haematol.2026.301102

Source records